The FDA has opened applications for a new Expedited IND Pilot that pairs drug sponsors with Qualified Research Institutions to speed up the path to first-in-human trials, with applications due October 30, 2026.
Avance Biosciences is hiring a Scientific Account Manager in Houston, TX — a great next step for PhD-level scientists ready to trade the bench for a client-facing role. Build relationships with biotech and pharma leaders, present our analytical and bioanalytical capabilities, and grow your career with hands-on mentorship and structured training. Apply today and help us connect great science with the people who need it...
Avance Biosciences will exhibit at BioProcess International and Cell & Gene Therapy International 2026, highlighting analytical support for mRNA therapeutics and RNA vaccines, on/off-target analysis, biodistribution analysis, whole genome sequencing, and potency testing. Visit our team at Booth #1402 to discuss analytical strategies for advancing biologics and next-generation therapies...
Keeping up with new FDA guidance documents can be challenging. The FDA regularly publishes new draft and final guidance covering topics ranging from drug development and manufacturing to diagnostics, biologics, cell and gene therapy, medical devices, and regulatory policy...
GentiBio recently presented genome editing safety data during the “On- and Off-Target Method Development” session st the 2026 ASGCT Meeting, highlighting the extensive off-target characterization strategy used to support development of GNTI-122, an engineered regulatory T cell (Treg) therapy for type 1 diabetes (T1D). The presentation is particularly timely given the recent FDA [...]
Avance Biosciences will be exhibiting at the ASGCT Annual Meeting in Boston, May 11–15, 2026. Visit Booth #1062 to connect with our team and learn how our bioanalytical and CMC testing services support cell and gene therapy development[...]
The FDA’s new draft guidance on genome editing safety marks a significant step toward more standardized, data-driven evaluation of gene therapies. With next-generation sequencing (NGS) at the core, the guidance outlines clear expectations for assessing off-target effects, genomic integrity, and rare editing events, providing sponsors with a more defined regulatory path for IND and BLA submissions.
Avance Biosciences is pleased to announce that we will be exhibiting at the 20th WRIB (Workshops on Recent Issues in Bioanalysis), taking place April 13–17, 2026, in Dallas, Texas. This premier industry event brings together leading scientists, regulators, and bioanalytical experts from across the global pharmaceutical and biotechnology community to discuss the latest advancements, challenges, and regulatory expectations in bioanalysis..[...]
Avance Biosciences will be exhibiting at the World Vaccine Congress in Washington, DC, where we will highlight our analytical testing services that support vaccine development programs. Our team provides potency assay development, next-generation sequencing, and cell-based assays designed to help advance RNA therapeutics and mRNA vaccine candidates from research through regulatory submission.[...]
Avance Biosciences will be exhibiting at Festival of Biologics USA 2026 in San Diego. Visit us at Booth #322 to learn how our CGMP-, GLP-, and CLIA-compliant bioanalytical services support biologics development, from assay development and validation to potency, immunogenicity, and advanced analytical testing[...]
Avance Biosciences is a leading Contract Research Organization (CRO) and Contract Testing Organization (CTO) providing CGMP and GLP-compliant analytical and bioanalytical services to support drug development. From early discovery through clinical development and commercialization, we provide CGMP and GLP-compliant services tailored to your therapeutic modality and regulatory needs.
